炎症性肠病孕妇暴露于维得利珠单抗对母亲和新生儿似乎风险较低:首项前瞻性比较研究
该研究前瞻性收集330例连续炎症性肠病妊娠数据,比较维得利珠单抗(VDZ,n=24)、抗肿瘤坏死因子(n=82)或常规治疗(n=224)的孕妇。三组孕产次相似,VDZ组多为克罗恩病且均非生物制剂初治,活动期受孕率显著更高(P<0.05),孕期 flare 更少。作者认为VDZ孕期似乎风险较低,但需进一步研究。
要点
- VDZ组活动期受孕率显著高于其他组(P<0.05)。
- VDZ组孕期 flare 较少。
- 作者认为VDZ孕期似乎风险较低,但需进一步研究。
核心结论
- 尽管需要进一步研究,维得利珠单抗在孕期似乎风险较低。
研究设计与样本
- 前瞻性收集330例连续炎症性肠病妊娠的数据。
- 孕妇接受维得利珠单抗(n=24)、抗肿瘤坏死因子(n=82)或常规治疗(n=224)。
主要发现
- 三组孕产次相似。
- 维得利珠单抗组主要由克罗恩病患者组成,且均非生物制剂初治。
- 维得利珠单抗组活动期受孕率显著更高(P<0.05),孕期 flare 更少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established. DESIGN: Data of 330 consecutive pregnancies with IBD was prospectively collected. RESULTS: Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy. DISCUSSION: Although further study is needed, VDZ appears of low risk during pregnancy.
引用
- Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. Am J Gastroenterol. 2019. PMID: 30920987. doi:10.14309/ajg.0000000000000186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。